| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Institut für Mikrobiologie und Hygiene, Charité University Medical Center, Berlin, Germany;
Biochemical Pharmacology, Department of Biology, University of Konstanz, Konstanz, Germany;
Institut für Medizinische Diagnostik, Berlin, Germany;
Private Medical Office, Kraichtal, Germany;
¶ Department of Medicine III, Rheumatology and Clinical Immunology, Charité University Medical Center, Berlin, Germany;
|| Department of Neurology, Charité University Medical Center, Berlin, Germany; and
# Pediatric Infectious Diseases, Cedars-Sinai Medical Center, Los Angeles, CA 90048
Lyme disease (LD) is caused by Borrelia burgdorferi and displays different stages, including localized, early disseminated, and persistent infection, all of which are associated with profound inflammatory reactions in the host. Induction of proinflammatory cytokines by B. burgdorferi is mainly mediated by outer surface proteins interacting with TLR-2/TLR-1 heterodimers. In this study, we show that TNF-
induction by Borrelia lysate was impaired in heterozygous TLR-2 knockout mice, while reactivity to lipoteichoic acid, another TLR-2 ligand signaling via TLR-2/TLR-6 heterodimers, was unaffected. Blood from individuals heterozygous for the TLR-2 polymorphism Arg753Gln was tested for cytokine release upon stimulation with Borrelia lysate, and induction of TNF- and IFN-
was significantly lower as compared with individuals not exhibiting this variation. Overexpression of TLR-2 carrying the Arg753Gln polymorphism in HEK 293 cells led to a significantly stronger impairment of activation by TLR-2/TLR-1 ligands as compared with TLR-2/TLR-6 ligands. To study whether heterozygosity for the Arg753Gln variant of TLR-2 influenced susceptibility for LD, we analyzed 155 patients for this polymorphism. The Arg753Gln variant occurs at a significantly lower frequency in LD patients as compared with matched controls (5.8 vs 13.5%, odds ratio 0.393, 95% confidence interval 0.17–0.89, p = 0.033), with an even more pronounced difference when late stage disease was observed (2.3 vs 12.5%, odds ratio 0.163, 95% confidence interval 0.04–0.76, p = 0.018). These data suggest that Arg753Gln may protect from the development of late stage LD due to a reduced signaling via TLR-2/TLR-1.
This article has been cited by other articles:
|
|
 |
|
  C. Hermann Review: Variability of host pathogen interaction Innate Immunity, August 1, 2007; 13(4): 199 - 218. [Abstract] [PDF]
|
|
|
|
 |
|
 C. M. Johnson, E. A. Lyle, K. O. Omueti, V. A. Stepensky, O. Yegin, E. Alpsoy, L. Hamann, R. R. Schumann, and R. I. Tapping Cutting Edge: A Common Polymorphism Impairs Cell Surface Trafficking and Functional Responses of TLR1 but Protects against Leprosy J. Immunol., June 15, 2007; 178(12): 7520 - 7524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Merx, M. Neumaier, H. Wagner, C. J Kirschning, and P. Ahmad-Nejad Characterization and investigation of single nucleotide polymorphisms and a novel TLR2 mutation in the human TLR2 gene Hum. Mol. Genet., May 15, 2007; 16(10): 1225 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Gautam, Ashish, L. D. Comeau, J. K. Krueger, and M. F. Smith Jr. Structural and Functional Evidence for the Role of the TLR2 DD Loop in TLR1/TLR2 Heterodimerization and Signaling J. Biol. Chem., October 6, 2006; 281(40): 30132 - 30142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Zager, A. C. M. Johnson, S. Lund, and S. Hanson Acute renal failure: determinants and characteristics of the injury-induced hyperinflammatory response Am J Physiol Renal Physiol, September 1, 2006; 291(3): F546 - F556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ghosh, R. Seward, C. E. Costello, B. D. Stollar, and B. T. Huber Autoantibodies from Synovial Lesions in Chronic, Antibiotic Treatment-Resistant Lyme Arthritis Bind Cytokeratin-10 J. Immunol., August 15, 2006; 177(4): 2486 - 2494. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
